No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
OLMA240517C10000
- 0.50
- -0.50-50.00%
15min DelayClose May 15 15:59 ET
1.15High0.50Low
1.15Open1.00Pre Close227 Volume271 Open Interest10.00Strike Price13.02KTurnover188.34%IV6.60%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.50Time Value100Contract SizeAmericanOptions Type0.4878Delta0.2807Gamma19.70Leverage Ratio-0.1534Theta0.0003Rho9.61Eff Leverage0.0030Vega
Intraday
- 5D
- 1D
News
Buy Rating Justified by Promising Efficacy and Safety Profile of Olema Pharmaceuticals' Drug Combination in Clinical Studies
Express News | HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target
Promising Clinical Trial Results Bolster Buy Rating for Olema Pharmaceuticals
OPEN, BCRX and AWIN Among Pre-market Gainers
Olema Pharmaceuticals Announces Promising Breast Cancer Trial Results
Express News | Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients
Comments
Although the sale doesn't necessarily signify a negative view on the company's future, absence of insider buying could induce concerns. Other company risks should be considered when investing.
President Sean Bohen Sold A Bunch Of Shares In Olema PharmaceuticalsMr. Garland's expertise in biopharma is predicted to boost late-stage development of Olema's lead product. This could solidify the company's influence in shaping next-gen therapies for women's cancers.
$Olema Pharmaceuticals(OLMA.US$ Olema Pharmaceuticals Announced New Preclinical Data Regarding The Discovery Of Novel Compounds Targeting KAT6, An Epigenetic Target That Is Dysregulated In Breast And Other Cancers
2
Read more